魅影直播

The UK government has announced a new

The 魅影直播 is disappointed that the deal does not appear to address longstanding industry concerns about intellectual property protections for UK life science innovators within the Indian market, particularly the need for regulatory data protection. This will prevent our sector from realising the true potential of this deal.

In response to the news, Richard Torbett, 魅影直播 Chief Executive, said: 鈥淎s one of the UK鈥檚 largest exporting sectors, it鈥檚 disappointing that this deal seemingly won鈥檛 support the UK鈥檚 growth ambitions for pharmaceuticals.

鈥淩obust intellectual property protections are fundamental for the innovation our companies deliver, but we believe an opportunity has been missed by the UK to demonstrate a commitment to high IP standards for our sector in this agreement.

鈥淲e urge the government to use ongoing negotiations with other key trading partners, including the EU, US, and Switzerland, to deliver agreements that better support Britain鈥檚 pharmaceutical industry.鈥�

Key facts about the UK pharmaceutical sector:

• The pharmaceutical industry invests 拢9 billion a year in UK research and development
• The industry delivers 拢17.6 billion in direct gross value added (GVA) to the British economy
• The pharmaceutical sector is the UK鈥檚 third-largest good exporting industry at 拢26.1 billion.
• The medicinal and pharmaceutical products are in the top 5 goods imported to the UK from India in the four quarters to the end of Q3 2024, accounting for 拢656.9 million, 6.3% of total goods imported
• The UK exported 拢127.14 million in medicinal and pharmaceutical products to India in 2024. [1]